Changes in Hong Kong stocks | Yiming Enko-B (01541) rose more than 7% to submit IMM2510 phase III clinical trial application

Zhitongcaijing · 10/02/2025 06:17

The Zhitong Finance App learned that Yiming Onko-B (01541) rose by more than 7%. As of press release, it had risen 7.3% to HK$14.4, with a turnover of HK$29.212 million.

According to the news, Yiming Angke announced this morning that the Group has submitted an application for IMM2510 for the phase III clinical trial of IMM2510 to treat immunotherapy-resistant (IO) resistant non-small cell lung cancer (NSCLC) to the Drug Evaluation Center of the State Drug Administration, and recently submitted two phase III registered clinical trials for different types of lung cancer.

Phase I study data published at the 2025 World Lung Cancer Congress recently showed that for 17 evaluable patients with advanced squamous non-small cell lung cancer (SQ-NSCLC) who had received immunotherapy, IMM2510 achieved an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% (13/17). The median duration of remission (DoR) was 7.59 months (95% CI: 4.07 -NA), and the median progression-free survival (PFS) was 9.4 months (95% CI: 1.87 -NA).